Recent advances in the treatment for gynecologic oncology  

作　　者：Lei Li Jinghe Lang 

机构地区：[1]Department of Obstetrics and Gynecology,Peking Union Medical College Hospital,Shuaifuyuan No.1,Dongcheng District,Beijing 100730,China [2]National Clinical Research Center for Obstetric&Gynecologic Diseases,Shuaifuyuan No.1,Dongcheng District,Beijing 100730,China [3]State Key Laboratory for Complex,Severe and Rare Diseases,Peking Union Medical College Hospital,Shuaifuyuan No.1,Dongcheng District,Beijing 100730,China

出　　处：《Holistic Integrative Oncology》2024年第1期706-709,共4页整合肿瘤学(英文)

基　　金：supported by the State Key Laboratory for Complex,Severe and Rare Diseases in Peking Union Medical College Hospital。

摘　　要：This commentary summarized the most important findings in the first half 2023 year based on Society of Gynecologic Oncology(SGO)annual meeting and publications in crucial journals.This commentary provided a comprehensive overview of notable developments in the field of gynecologic oncology throughout the first half of 2023,drawing insights from the Society of Gynecologic Oncology(SGO)Annual Meet-ing and pivotal publications in esteemed journals.The discourse delved into the forefront of molecular mechanisms,emphasizing critical themes such as homologous recombination repair deficiency,mismatch repair,immune check-point blockades,and anti-angiogenesis in various cancers.Specific attention was given to advancements in targeted and immunotherapeutic modalities,notably examining the efficacy and safety profiles of poly(ADP-Ribose)poly-merase inhibitors(PARPi)in ovarian cancer.Conclusively,the commentary underscored the transformative impact of molecularly guided therapies,marking them as pivotal in addressing refractory conditions and set the stage for heightened expectations in future advancements.PARP inhibitors have become the standard maintenance treatment for ovarian cancer.Among the first six articles,two(SOLO1 and PAOLA-1)summarized evidence supporting the improvement of overall survival with PARP inhibitors in maintenance therapy,while the NOVA study reported no benefit in overall survival.The first,fourth,and sixth arti-cles discussed the feasibility of PARP inhibitors,immune checkpoint inhibitors used alone or in combination in neo-adjuvant therapy(post-chemotherapy surgery).The latter two articles focused on the application of PD-1(immune checkpoint inhibitors)in locally advanced cervical cancer,demonstrating enhanced efficacy.Currently,immune checkpoint inhibitors are commonly used in advanced cervical and endometrial cancers due to their status as hot tumors.Their use,either alone or in combination with anti-angiogenic drugs,has shown better outcomes in recur-rent and advanced refractory endometrial and

关 键 词：Gynecologic cancer Targeted therapy IMMUNOTHERAPY PD-1 blockage Poly(ADP-Ribose)polymerase inhibitors 

分 类 号：R73[医药卫生—肿瘤]